1. Scrip
  2. >>Therapy Areas
  3. >>Immunological

Clinical Data And Cash: Inflammation Focused InflaRx Hots Up

 
• By Sukaina Virji

Positive Phase II data in sepsis and a €31m private financing round: 2016 has been a busy year for inflammation focused German biotech InflaRx.

InflaRx GMBH, based in Jena, Germany, raised €31m in July this year to advance Phase II development of its lead drug candidate IFX-1, a first-in-class monoclonal anti-complement C5a antibody.

The plan is to use the funds to pursue IFX-1 in various acute and chronic inflammatory indications. In January, InflaRx...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Immunological

More from Therapy Areas

Lyra Eyes US Filing For LYR-210 After Surprise ENLIGHTEN 2 Win

 
• By Sushmita Panda

In a turn of fortunes, Lyra Therapeutics has reported positive Phase III results for LYR-210 in chronic rhinosinusitis, boosting hopes for US approval. The company plans to submit an NDA and pursue further trials, but its cash position is precarious.

Ascletis Plans China Submission After Positive Denifanstat Phase III Acne Results

 
• By Sushmita Panda

Once-daily oral FASN inhibitor denifanstat meets all endpoints in a Chinese Phase III trial for moderate-to-severe acne, paving the way for a regulatory submission in China.

New Regenxbio DMD Data Support Gene Therapy Accelerated Approval

 
• By Joseph Haas

Regenxbio reported functional and biomarker data from an ongoing study of RGX-202, which it hopes to file for approval in Duchenne muscular dystrophy in 2026.